XenoPort, Inc. (NASDAQ:XNPT)
CAPS Rating:
A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
RSS Headlines
Fool UK
Recs
It should be wait what FDA say for this REJECT.
And, we can do something for this company.
I am waiting for a while.
I believe what XNPT did well.